Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

NCT03614156 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

363

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision to stop the program.

Conditions

Depressive Disorder, Major

Interventions

DRUG: Rapastinel
DRUG: Placebo

Sponsor

Naurex, Inc, an affiliate of Allergan plc